This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Buy ADC Therapeutics (ADCT) Ahead of Earnings?
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 39.18% and 69.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 16.67% and -34.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics SA (ADCT) Upgraded to Buy: Here's Why
by Zacks Equity Research
ADC Therapeutics SA (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?
by Zacks Equity Research
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.
Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
by Zacks Equity Research
Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.
Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y
by Zacks Equity Research
Bayer (BAYRY) misses both earnings and sales estimates in the third quarter of 2020.
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales
by Zacks Equity Research
Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.